ENTX

Entera Bio Ltd. is a clinical-stage biotechnology company developing orally delivered large molecule therapeutics using its proprietary drug delivery technology. The company's platform enables the oral administration of proteins and peptides that traditionally require injection, improving patient convenience and compliance. Entera's lead product candidate is an oral formulation of parathyroid hormone for treating osteoporosis and hypoparathyroidism. The company is also developing oral delivery formulations for other therapeutic proteins in various disease areas.